A basic primer on amino acids as protein building blocks and how linking them creates peptides. Evergreen background, nothing new.
Recap by typeshit. Post by Facebook on Facebook.
The once-daily pill blocks the IL-23 receptor and helped people with moderate to severe ulcerative colitis respond more often than placebo, a new study reports.
Bikman welcomes a new result but argues the likely cause is tirzepatide bringing insulin down rather than the drug slowing aging itself. His view, not a study claim.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Regen says the placebo group saw a 9% drop, while people on retatrutide also lost 31 lb on average and saw systolic blood pressure fall 14 points.
AG Information Network of the West looks at GLP-1 users' effect on protein demand, alongside news on a US trade deal with Mexico.
8:25
The I looked into channel digs into the retatrutide trial data to ask how much of the weight lost on the triple agonist may come from muscle.
Loading…